RT Journal Article
SR Electronic
T1 Incidence and Epidemiological study of COVID-19 in Nagpur urban region (India) using Molecular testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.11.21256719
DO 10.1101/2021.05.11.21256719
A1 Tanna, Jay
A1 Singha, Bishwadeep
A1 Nayak, Amit R.
A1 Husain, Aliabbas A.
A1 Raje, Dhananjay V.
A1 Desai, Shubhangi A.
A1 Deshmukh, Madhavi
A1 Mundhada, Shailendra
A1 Kashyap, Rajpal S
YR 2021
UL http://medrxiv.org/content/early/2021/05/11/2021.05.11.21256719.abstract
AB The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) virus has emerged as public health emergency affecting 206 countries worldwide. India is second highest currently worst effected by Covid 19 pandemic with close to 12.6 million cases and 1.6K deaths reported till date. Maharahstra is the highest Covid-19 burden state in India reporting quarter of overall cases. The city of Nagpur, in Maharashtra state, ranks 4th in terms of reported COVID-19 cases, with 2.5 lakh incidences and more than 4,000 deaths As the transmission rate of COVID-19 is high, it is imperative to study its disease epidemiology in regions of high endemicity to bolster our understanding of its spread, transmission dynamics and contact tracing to undertake appropriate public health control measures.. The present study was undertaken to study the incidence and trend of COVID-19 infection from various zonal regions of Nagpur city, using real time PCR (RT PCR). A retrospective study was carried out at Indian Council of Medical Research (ICMR) approved private molecular diagnostic laboratory in Nagpur from period of 4th May 2020 to 14th November 2020. A total of 51,532 samples collected from various zonal regions of the city during the study period were processed for SARS CoV-2 RT-PCR. Patient information was collected using a pre-defined study proforma which included demographic details such as name, age, gender, address, along with other information, like details of sample collected, kits used and date of sample collected and processed. The study reports an overall Covid-19 positivity of 34% in Nagpur region. The zone wise distribution of positive cases indicated high rate of COVID-19 in endemic regions of Nagpur such as Satranjipura (49%), Ashi nagar (44%), Gandhibagh (43%) & Lakadganj (43%). Rates of infection were high in economically productive age group (21-40) with males being more vulnerable than females. The result of present epidemiology study highlights important data with respect to regions of endemicity within Nagpur city zones. The present data has high public health importance and will be useful for local civic bodies and other community stake holders to undertake appropriate control measures in future epidemic waves of Covid 19. Interestingly, the Government’s reduction in testing rates has been helpful in increasing testing per day. The authorization of private laboratories has also increased testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for the current studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Institutional Ethical Committee of Dr. G. M. Taori Central India Institute of Medical Sciences (CIIMS),Nagpur. Approvals to conduct RT-PCR in Human samples was provided by Indian Council of Medical Research (ICMR), Govt of India. Registration Number (DPMDLN)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA